foxo4-dri cancer The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI 10mg
FOXO4 DRI 10mg FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24



